Shots:
- The NMPA has approved IND application to initiate P-Ib/II trial of opamtistomig (LBL-024) in combination therapy for metastatic colorectal cancer (mCRC)
- Trial will evaluate the safety & efficacy of opamtistomig combination regimens in pts with mCRC & explore potential predictive biomarkers. Opamtistomig mechanism was already validated across EP-NEC, NSCLC, SCLC, & biliary tract cancer
- Opamtistomig is a bispecific antibody that blocks PD-1/PD-L1-mediated immunosuppression & conditionally activates 4-1BB co-stimulatory signaling, restoring T-cell function & promoting proliferation and memory formation
Ref: Globenewswire | Image: Leads Biolabs | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
